AptarGroup reports Q1 adjusted EPS $1.20, consensus $1.15

Reports Q1 revenue $887M, consensus $898.64M. “Our pharma and closures segments delivered solid results with increased product sales in the quarter. We saw growing demand for our dosing, dispensing and protection technologies across a number of end markets including central nervous system therapeutics, emergency medicines, weight and diabetes management, as well as food, beverage and personal care. We also returned about $110 million to shareholders through dividends and share repurchases, more than half a million shares were repurchased for $80 million,” said Stephan B. Tanda, Aptar President and CEO.